Abstract

The goal of the project is to investigate the relationship between angiogenesis in stage II, III or IV breast cancer and clinical outcome. Parameters to be measured include circulating and urinary basic fibroblast growth factor (bFGF), degree of neovascularization and tissue TGF- B1 expression. Specimens to be analyzed have been or will be collected from women participating in prospective therapeutic trials of CALGB. Analysis will allow a correlation of angiogenesis and putative markers (circulating or urinary bFGF and tissue TGF-B1) with treatment outcome.Such knowledge could lead to clinically useful predictors of prognosis.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA064057-02
Application #
2106300
Study Section
Special Emphasis Panel (SRC (80))
Project Start
1994-06-01
Project End
1998-03-31
Budget Start
1995-04-13
Budget End
1996-03-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215